top of page
  • master948

Webinar : Unveiling Tomorrow’s Cancer Solutions: A Deep Dive into Radiopharmaceuticals, Dosimetry, and AI Integration






Over the past 30 years, the risk of dying from cancer has consistently decreased, saving approximately 4 million lives in the United States. Despite this positive trend, 2024 is projected to mark a milestone with an estimated two million new cancer cases, presenting a new challenge.

In the field of cancer treatment, the growing interest in radiopharmaceuticals and dosimetry is evident. The increasing demand for personalized medicine applications and their impact on clinical outcomes suggests a rising need for tailored dosage and treatment for each patient’s cancer profile.


Presenter : Jon DeVries, MBA, Chief Executive Officer, Mirada Medical

Jon DeVries has more than 20 years of experience spearheading the creation and release of innovative cloud-based healthcare initiatives that bring advanced services and technologies to providers and researchers, with the goal of improving patient care.


Presenter : Mark Crockett, MD, Chief Medical Officer, Mirada Medical; President, TeleDaaS

Dr. Mark D. Crockett, MD, FACEP has been in HCIT leadership for more than 20 years, with Chief Medical Officer positions at Optum, Best Doctors, and Picis. He has led organizations in several areas of healthcare software, including electronic medical records, population health, and most recently patient safety and compliance. During much of that time, he practiced Emergency Medicine at Advocate Healthcare in Chicago. 


Presenter : Jess Guarnaschelli, MD, Senior Medical Director, Medical Department, Medpace

Dr. Jess Guarnaschelli is board-certified by the American Board of Radiology in Radiation Oncology, Radiation Biology and Radiation Physics. She brings more than twenty years of experience in clinical research, academia, and clinical radiation oncology. Dr. Guarnaschelli is well-versed in Phase I radiopharmaceutical clinical trial design having worked with many radioisotopes, radiopharmaceuticals, and solid tumor indications. Prior to joining Medpace,



Comments


bottom of page